Article Details
Retrieved on: 2018-03-02 00:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div><b>Benchmark Capital</b> Advisors, a New York-based fund reported 98,034 shares. Ratings analysis reveals 33% of Bristol-Myers Squibb Co's analysts are positive. Out of 3 Wall Street analysts rating Bristol-Myers Squibb Co, 1 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $52.0 ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here